Globus Medical (NYSE:GMED) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPS

Globus Medical (NYSE:GMED) posted its earnings results on Thursday. The medical device company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.24, FiscalAI reports. The firm had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a return on equity of 14.73% and a net margin of 17.02%.The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 earnings per share. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Positive Sentiment: Q2 revenue rose 5.9% to $789.6 million, while base-business revenue excluding Nevro increased 9%; adjusted EPS jumped 56% to a record $1.34.
• Positive Sentiment: U.S. spine grew 7%, international spine rose 14% as reported, and trauma increased 31%, supported by new products, competitive sales-force recruiting, improved inventory availability, and continued market-share gains.
• Positive Sentiment: Adjusted gross margin expanded 200 basis points to 69.4% and adjusted EBITDA margin reached 35.4%; management raised 2026 non-GAAP EPS guidance to $4.95-$5.05 while maintaining revenue guidance of $3.18-$3.22 billion.
• Negative Sentiment: Nevro sales declined 14.3% year over year and fell sequentially, while enabling-technology revenue dropped 25.8% as the company shifts toward leasing and other flexible capital-acquisition models. Management expects Nevro trial volumes to recover by late Q4, but identified both businesses as risks to second-half revenue.
• Positive Sentiment: Globus repurchased $136.1 million of shares in Q2 and has $253.9 million remaining under its authorization; it also expects to launch patient-specific SCRIPT lumbar spacers and rods in Q3, adding to a pipeline of more than 60 development projects.

Globus Medical Stock Performance

Globus Medical stock traded up $1.12 during midday trading on Friday, hitting $82.20. 3,299,652 shares of the company’s stock were exchanged, compared to its average volume of 1,551,427. Globus Medical has a 12-month low of $54.15 and a 12-month high of $101.40. The stock has a market cap of $11.16 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 1.67 and a beta of 0.95. The firm’s 50 day simple moving average is $79.33 and its 200 day simple moving average is $85.23.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

A number of hedge funds have recently added to or reduced their stakes in GMED. AQR Capital Management LLC grew its stake in shares of Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after purchasing an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC raised its stake in shares of Globus Medical by 33.0% during the first quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after purchasing an additional 1,085 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Globus Medical by 38.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after purchasing an additional 8,540 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Globus Medical by 237.3% during the first quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock worth $62,000 after purchasing an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after purchasing an additional 28,027 shares during the period. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial lowered their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a report on Thursday, July 16th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Monday, July 13th. UBS Group initiated coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They set a “neutral” rating and a $82.00 price target on the stock. Finally, Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $101.77.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.